Bridged Bicyclo Compounds, Heterocyclic
"Bridged Bicyclo Compounds, Heterocyclic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Heterocyclic compounds that contain two rings that share two non-adjacent atoms in common.
Descriptor ID |
D019086
|
MeSH Number(s) |
D03.605.084
|
Concept/Terms |
Bridged Bicyclo Compounds, Heterocyclic- Bridged Bicyclo Compounds, Heterocyclic
- Bicyclo Compounds, Heterocyclic
- Heterocyclic Bicyclo Compounds
- Bicyclic Heterocyclic Compounds
- Heterocyclic Compounds, Bicyclic
- Heterocyclic Cpds, Bicyclic
- Bicyclic Heterocyclic Cpds
|
Below are MeSH descriptors whose meaning is more general than "Bridged Bicyclo Compounds, Heterocyclic".
Below are MeSH descriptors whose meaning is more specific than "Bridged Bicyclo Compounds, Heterocyclic".
This graph shows the total number of publications written about "Bridged Bicyclo Compounds, Heterocyclic" by people in this website by year, and whether "Bridged Bicyclo Compounds, Heterocyclic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 1 | 1 | 2 |
1998 | 1 | 0 | 1 |
1999 | 1 | 0 | 1 |
2000 | 1 | 0 | 1 |
2001 | 0 | 2 | 2 |
2002 | 1 | 1 | 2 |
2003 | 0 | 2 | 2 |
2004 | 1 | 1 | 2 |
2005 | 1 | 4 | 5 |
2006 | 0 | 1 | 1 |
2007 | 2 | 0 | 2 |
2008 | 1 | 0 | 1 |
2012 | 0 | 1 | 1 |
2014 | 0 | 3 | 3 |
2016 | 1 | 2 | 3 |
2017 | 1 | 2 | 3 |
2018 | 2 | 1 | 3 |
2020 | 1 | 1 | 2 |
2021 | 3 | 5 | 8 |
2022 | 0 | 1 | 1 |
2023 | 0 | 2 | 2 |
2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Bridged Bicyclo Compounds, Heterocyclic" by people in Profiles.
-
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood Cancer J. 2024 02 20; 14(1):32.
-
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024 Apr; 99(4):615-624.
-
A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma. Blood Adv. 2023 07 11; 7(13):2983-2993.
-
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. Lancet. 2023 08 19; 402(10402):641-654.
-
Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia. Clin Cancer Res. 2022 07 01; 28(13):2744-2752.
-
Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine. J Clin Oncol. 2022 03 10; 40(8):855-865.
-
Tracking the movement of discrete gating charges in a voltage-gated potassium channel. Elife. 2021 11 15; 10.
-
Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase 1b study (GO28440). Haematologica. 2021 11 01; 106(11):2834-2844.
-
Venetoclax imparts distinct cell death sensitivity and adaptivity patterns in T cells. Cell Death Dis. 2021 10 27; 12(11):1005.
-
Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood Adv. 2021 10 12; 5(19):3748-3759.